Adaptive Biotechnologies Corporation

ADPT Healthcare Diagnostics & Research

Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024. In the quarter to June 2026, revenue grew 21.5%, EPS fell 47.1% and free cash flow grew 42.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

24.02 1.56 −6.10%
Market cap
$4.1B
P/E
0.0×
Fwd P/E
−36.6×
Dividend yield
—
F-score
6/9
Altman Z
2.08
Beneish M
−2.44
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 6 6 5
ROE
(37.22%) (27.84%) (23.97%) (38.68%)
ROA
(15.18%) (11.31%) (9.77%) (11.23%)
ROIC
0.00% 0.00% (494.38%) (16.57%)
Return on Tangible Assets
(33.80%) (24.35%) (21.09%) (17.62%)
Average Days of Receivables
64.73 66.37 59.70 58.66
Free Cash Flow per Share
(0.41) (0.32) (0.19) (0.15)
Free Cash Flow
(62.93) (48.94) (29.53) (24.03)
Other line items

Show all line items

Columns are period end dates